Drugs / EXG-5003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04863131 | Apr 2021 → Dec 2022 | COVID-19 | Fujita Health University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EXG-5003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04863131 ↗ |
| Modality | Messenger RNA (mRNA) | “COVID-19 self-replicating mRNA vaccine” NCT04863131 ↗ |